Analytical Data
-
Gene name
CD1D-B2M Heterodimer
- Application
-
Alternative Names
Antigen-presenting glycoprotein CD1d; CD1d; R3G1; Beta-2-microglobulin; B2M
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P15813 (E20-S301)&P61769
-
Expression Region
P15813 (E20-S301)&P61769 (I21-M119)
-
Molecular Weight
50-55 kDa and 17 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The CD1D-B2M heterodimer is a crucial component of the immune system, primarily involved in the presentation of lipid antigens to T cells. CD1D, a member of the CD1 family of glycoproteins, is responsible for the recognition of glycolipids and is expressed on various immune cells, including dendritic cells and B cells. β2-microglobulin (B2M) is an essential protein that stabilizes the structure of CD1D, enabling its function in antigen presentation. Research on the CD1D-B2M heterodimer has garnered significant interest due to its role in facilitating the activation of NKT (natural killer T) cells, which are pivotal in bridging innate and adaptive immunity. Studies have shown that these cells play a vital role in various immune responses, including tumor surveillance and the regulation of autoimmune diseases. Understanding the structural and functional dynamics of the CD1D-B2M heterodimer can provide insights into its involvement in immune regulation and disease mechanisms. Recent advances in recombinant protein technology have enabled the production and study of this heterodimer, paving the way for potential therapeutic applications, including vaccine development and immunotherapy. By exploring the interactions and functionalities of this complex, researchers aim to leverage its properties for innovative approaches in treating infectious diseases, cancer, and autoimmune disorders. The investigation of CD1D-B2M not only enhances our understanding of lipid antigen presentation but also opens new avenues for harnessing the immune system in clinical settings.
